1. (aka---how to know where to look and who to call)

2.  Rare disease, 5000-7000 new cases of GIST every year  Compare 230,000 new invasive breast CA cases/year  GIST studies tend to be opened at fewer sites  OHSU(Portland), Dana Farber (Boston), Fox Chase (Philadelphia), MD Anderson (Houston), Memorial Sloan Kettering (New York)

3.  Oregon - 12  California -12  Washington - 9  Colorado - 4  Nebraska - 2  Alaska  Arkansas  Hawaii  Idaho -2  Illinois  Indiana  Michigan  South Carolina  Tennessee  Nigeria 9 12 2 1 1 1 1 4 1 2 1 1 1

4.  Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.  Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.  Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.  Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use Source: http://www.nlm.nih.gov/services/ctphases.htmlhttp://www.nlm.nih.gov/services/ctphases.html

5.  Check with your insurance  Does your insurance allow you to participate?  Myth: Clinical trials do NOT “pay for everything”  As of January 1, 2014, the Affordable Care Act (ACA) includes the requirement that private insurers cover routine costs during participation in a clinical trial  At OHSU we will check this for you prior to study participation

6.  KIT (exon 9/11/13/17)  PDGFRA D842V (exon 12/14/18)  Wild Type--- what does that mean?  Recommend getting tissue mutation testing ASAP (with first biopsy or surgery)  At a minimum, mutation testing after Imatinib (Gleevec) failure  Do not usually need another biopsy/surgery to get this done

7. Source: Michael Heinrich, MD

8.  Date of diagnosis  Keep a copy of your pathology report(s)  Date(s) of surgery(ies) and location(s) where surgery was done  Previous treatments and dates (why did you come off treatment?)---be specific (was it for progression or for symptoms?)

9.  https://www.molecularmatch.com/ https://www.molecularmatch.com/  https://clinicaltrials.gov/ https://clinicaltrials.gov/

10.  BLU-285  Phase 1 oral TKI drug  Several sites open around the world  Visits weekly for the first month then roughly monthly  KTN-158  Phase 1 intravenous antibody drug  OHSU can enroll 1-3 patients/month for now  Requires infusion every 3 weeks indefinitely

11.  SARC 029 trial  Likely to open later this summer  Phase II study combining two different oral drugs

12.  Tracy Walker, RN, BSN  OHSU Knight Cancer Institute  walkertr@ohsu.edu walkertr@ohsu.edu  503-346-1183